ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Avigan coronavirus hope puts Fujifilm's health care in focus

Drug trial in China highlights company's industrial transformation through M&A

Under CEO Shigetaka Komori, Fujifilm has transformed itself through dealmaking. (Photo by Akira Kodaka)

TOKYO -- Fujifilm continues to call itself a photographic filmmaker, but the Tokyo-based company sees its future in the health care business.

The idea may sound over the top but it was brought sharply into focus on Wednesday after Chinese authorities said Avigan, an anti-flu drug developed by Fujifilm's Toyama Chemical unit, had been shown in trials to be an effective treatment for the new coronavirus. Shares in Fujifilm rose 15%.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more